Weekly Report: what happened at LVTX last week (0422-0426)?

Weekly Report: what happened at LVTX last week (0415-0419)?

Weekly Report: what happened at LVTX last week (0408-0412)?

Weekly Report: what happened at LVTX last week (0401-0405)?

Analysts Offer Insights on Healthcare Companies: LAVA Therapeutics (LVTX), Acumen Pharmaceuticals (ABOS) and Advanced Medical Solutions (GB:AMS)

Weekly Report: what happened at LVTX last week (0325-0329)?

Weekly Report: what happened at LVTX last week (0318-0322)?

Buy Rating Affirmed for LAVA Therapeutics Amid Promising T-Cell Cancer Therapy Trials and Strong Financials

Leerink Partners analyst Daina Graybosch has maintained their bullish stance on LVTX stock, giving a Buy rating on March 22. The optimism stems from the company’s innovative T-cell engagers, particularly LAVA-1207, which targets prostate cancer.

LAVA Therapeutics: A Strong Buy on Robust Financials and Promising Oncology Pipeline Advancements

Analyst Reni Benjamin of JMP Securities reiterated a Buy rating on LAVA Therapeutics with a price target of $6.00. The positive progress of LAVA-1207 in clinical trials contribute to the Buy rating. The company is focused on transforming cancer treatment.

LAVA Therapeutics GAAP EPS of -$0.24 beats by $0.18

LAVA Therapeutics Announces Progress and Stability

Lava Therapeutics Price Target Maintained With a $6.00/Share by HC Wainwright & Co.

Strong Buy Rating for LAVA Therapeutics on Promising Clinical and Financial Outlook

LAVA Therapeutics Full Year 2023 Earnings: Revenues Disappoint

LAVA Therapeutics missed analyst estimates by 47%. The company's shares are up 13% from a week ago. Revenue is forecast to grow 60% p.a. On average during the next 3 years. The company has 4 warning signs that you should be aware of before investing.

HC Wainwright & Co. Reiterates Buy on LAVA Therapeutics, Maintains $6 Price Target

LVTX Stock Earnings: LAVA Therapeutics Misses EPS, Misses Revenue for Q4 2023

LAVA Therapeutics reported earnings per share of -24 cents. The company reported revenue of $353,000. This was 94.35% worse than the analyst estimate of $6.25 million. AVVA Therapeutic is down 2.7% today.

LAVA Therapeutics Q4 EPS $(0.24) Misses $(0.12) Estimate, Sales $353.00K Miss $6.25M Estimate

LAVA Therapeutics reported quarterly losses of $0.24 per share. The company missed the analyst consensus estimate by 100 percent. AVVA also reported quarterly sales of $353.00 million which missed the estimate by 94.35%. The company's shares are down 8.8 percent in the last week.

Weekly Report: what happened at LVTX last week (0311-0315)?

Eton Pharmaceuticals, Inc. (ETON) Reports Q4 Loss, Lags Revenue Estimates

Weekly Report: what happened at LVTX last week (0304-0308)?